Enavail, whose solubilising technology was developed University of Texas in Austin, will base the facility at the nearby Abilene Life Sciences Accelerator (ALSA) complex in a construction project expected to complete this September.
Company president Brian Windsor said that: “We presently offer Phase I cGMP clinical batch production for compounds with applications in pulmonary, parenteral, intranasal and oral delivery. The Abilene facility will allow us to support all clinical phases as well as commercial manufacturing.
He went on to explain that ALSA was chosen as the site for the new plant after a thorough review of the available options and that: “The space and the services the Abilene Life Sciences Accelerator have to offer are a perfect fit for us.
While this may well be the case, the fact Emergent operates the complex and has already installed its Receptor Logic assay development services unit there must also have been a factor.